Biological therapies for obsessive-compulsive disorder

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Obsessive-compulsive disorder (OCD) has two primary evidence-based treatments: exposure and response (ritual) prevention (EX/RP) and pharmacotherapy with serotonin reuptake inhibitors (SRIs).
• This article, the third in a series, focuses on the biological treatment modalities for OCD.

Purpose of the Study:

• To review the efficacy of serotonin reuptake inhibitors (SRIs) as monotherapy for OCD.
• To discuss strategies for managing treatment-resistant OCD using various pharmacological and somatic therapies.
• To explore patient-treatment matching based on symptom clusters and provide guidance on maintenance and termination of treatment.

Main Methods:

• Review of existing literature on the efficacy of SRIs (clomipramine and SSRIs) for OCD monotherapy.
• Discussion of treatment-resistant OCD strategies, including combination therapies, augmentation, and intravenous clomipramine.
• Examination of other somatic therapies such as electroconvulsive therapy, neurosurgery, and transcranial magnetic stimulation.

Main Results:

• Evidence supports the efficacy of clomipramine and SSRIs as monotherapy for OCD.
• Various strategies exist for treatment-resistant OCD, including combining EX/RP with SRIs, combining different antidepressants, augmentation, and alternative somatic therapies.
• Research is ongoing regarding optimal treatment selection based on symptom clusters and management of long-term treatment.

Conclusions:

• SRIs are a cornerstone of biological treatment for OCD.
• A range of options are available for treatment-resistant OCD, requiring careful consideration of individual patient factors.
• Further research is needed to refine treatment selection, duration, and discontinuation protocols for OCD.